A PHASE 1, OPEN-LABEL, RANDOMIZED, SINGLE DOSE, PARALLEL GROUP STUDY TO ASSESS INJECTION SITE RELATIVE BIOAVAILABILITY OF PF-04950615 FOLLOWING SUBCUTANEOUS ADMINISTRATION IN ADULT SUBJECTS WITH HYPERCHOLESTEROLEMIA
Phase of Trial: Phase I
Latest Information Update: 03 Jun 2019
Price : $35 *
At a glance
- Drugs Bococizumab (Primary)
- Indications Hypercholesterolaemia
- Focus Pharmacokinetics
- Sponsors Pfizer
- 05 Jan 2015 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record.
- 09 Oct 2014 Planned End Date changed from 1 Sep 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov record.
- 09 Oct 2014 Planned primary completion date changed from 1 Sep 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov record.